Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.
Also called NCT05528419
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 320 participants
- Registry
-
NCT05528419
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05528419. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (actual); primary completion 2026-01-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
- Condition
- Atrial Fibrillation Recurrent
- Condition
- Hypertension
- Intervention (Drug)
- Sacubitril-valsartan
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct05528419- Content hash
79aea747b156ff9e0c993bc1556e1aab16265912eef7a86a14aa368fe6415662